These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Morphologic changes in the epithelium of the uterine cervix in long-term administration of the 19-norsteroid-containing oral hormonal contraceptives Non-Ovlon and gravistat]. Geissler U Zentralbl Gynakol; 1988; 110(5):267-76. PubMed ID: 2453979 [TBL] [Abstract][Full Text] [Related]
3. Change to Tri-Regol from other oral contraceptives. Garamvölgyi G Ther Hung; 1991; 39(3):122-4. PubMed ID: 1818425 [TBL] [Abstract][Full Text] [Related]
4. The relationship between vascular headaches and low-dose oral contraceptives. Karsay K Ther Hung; 1990; 38(4):181-5. PubMed ID: 2094059 [TBL] [Abstract][Full Text] [Related]
5. [Serum prolactin levels in women using oral contraceptives (Gravistat)]. Mikrut W; Jeske W Ginekol Pol; 1985 Oct; 56(10):620-3. PubMed ID: 4092990 [No Abstract] [Full Text] [Related]
6. Observations with Anteovin in relation to age. Szigethy A Ther Hung; 1991; 39(1):11-5. PubMed ID: 1858069 [TBL] [Abstract][Full Text] [Related]
7. [Cutaneous effects in hormonal contraception]. Thomas P; Dalle E; Revillon B; Delecour M; Devarenne-nicolle MF; Pagniez I NPN Med; 1985 Jan; 5(81):19-24. PubMed ID: 12281276 [TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrine effects of long-term hormonal contraception. Balogh A Acta Med Hung; 1986; 43(2):97-102. PubMed ID: 3588164 [TBL] [Abstract][Full Text] [Related]
10. Mesenteric venous thrombosis associated with pregnancy and oral contraception. A case report. Graubard ZG; Friedman M S Afr Med J; 1987 Apr; 71(7):453. PubMed ID: 3563797 [TBL] [Abstract][Full Text] [Related]
11. [1st experiences with a new hormonal contraceptive agent Gravistat-Jenapharm]. Carol W; Klinger G; Böhm W; Hempel E Z Arztl Fortbild (Jena); 1976 Feb; 70(3):135-7. PubMed ID: 134513 [No Abstract] [Full Text] [Related]
12. Experience with hormonal contraceptives. Kulakov VI Acta Med Hung; 1986; 43(2):93-6. PubMed ID: 3588163 [TBL] [Abstract][Full Text] [Related]
13. [Incidence of toxic liver lesions due to Gravistat]. Link H; Metzner C; Ziesenhenn K Z Gesamte Inn Med; 1978 Mar; 33(6):187-9. PubMed ID: 645155 [TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of Rigevidon used for contraception]. Marianowski L; Grezechocińska B Ginekol Pol; 1984 Aug; 55(8):631-5. PubMed ID: 6396173 [TBL] [Abstract][Full Text] [Related]
15. Results of the multilateral study of Tri-Regol tablet. Seregély G Ther Hung; 1991; 39(3):136-41. PubMed ID: 1840164 [TBL] [Abstract][Full Text] [Related]
16. Changes in plasma HDL-cholesterol in women using oral contraceptives in Kenya. Maina FW; Sekadde-Kigondu CB; Ojwang PJ; Mati JK East Afr Med J; 1987 Jul; 64(7):442-7. PubMed ID: 3691360 [TBL] [Abstract][Full Text] [Related]
17. [Clinical study of the secondary effects associated with taking a triphasic anti-ovulatory contraceptive]. Vekemans M Rev Med Brux; 1984 Jan; 5(1):13-9. PubMed ID: 6701404 [TBL] [Abstract][Full Text] [Related]
18. [Systemic lupus erythematosus during therapy with oral estrogen-progestin. Considerations apropos of a case]. Gueli N; Toto A; Tartaglione E; Lucianetti MC; Screnci M; Sauli V; Carmenini G Clin Ter; 1987 May; 121(4):299-304. PubMed ID: 2973866 [No Abstract] [Full Text] [Related]
19. [Systemic changes during the use of hormonal contraceptives]. Manuilova IA; Trutko NS; Dubnitskaia LV; Kuramshina AKh Akush Ginekol (Mosk); 1983 Nov; (11):14-7. PubMed ID: 6666789 [TBL] [Abstract][Full Text] [Related]
20. Observations with a combined oral contraceptive (Rigevidon) containing minimum oestrogen dose. Karsay K Ther Hung; 1980; 28(1):17-20. PubMed ID: 7281074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]